SelectImmune Pharma AB was founded in 2017

Rather than killing bacteria directly with antibiotics, we develop new ways of equipping the host immune system to fight off the infections. Specifically, our innovations concern infectious disease and chronic inflammation, where we hope to make a significant impact on disease and health management.

• The company’s drug candidates act by strengthening the innate immune system.
• Our research drives drug development by deciphering the mechanisms that determine “evil versus good” inflammation
• Our drug candidates are endogenous inflammatory agents or new bacterial molecules that inhibit the immune system
• The research has been published in leading international journals, and 150-200 MSEK has funded research, so far.

Urinary tract infections are among the most common causes of death and the disease burden of UTI is significant. UTIs affects >150 million adults each year and 5% of children < 12 years old. Urinary tract infections are very common, costly and a major cause of morbidity and mortality. Selectimmune AB is pioneering studies of the molecular basis of UTI susceptibility and the consequences for diagnosis and therapy. By dissecting molecular interactions between bacteria and host, it is becoming possible to distinguish defensive from damaging aspects of the host defence and to develop therapies that strengthen the defence while avoiding chronicity and tissue damage.

Antibiotic victims threaten global public healthAcute need for new medicines for infectious diseases

Expected annual deaths caused byantibiotic resistance by 2050

• WHO appoints antibiotic resistance to a massive global threat to public health
• WHO defines a “post-antibiotic”, where common infections once again cause death
• Very high antibiotic resistance in bacteria that cause common infections such as pneumonia, sepsis, urinary tract infections and wound infections
• Few treatment options, even against severe, life-threatening infections.